Last updated on February 2017

Use of Biosimilar Nivestim to Prevent Chemo-induced Neutropenia. Real Life Study


Brief description of study

The aim of this study is to describe in real-life conditions the determinants of use of GCSF (Granulocyte Colony-Stimulating Factor) Nivestim® in primary or secondary prophylaxis and in patients receiving chemotherapy for solid tumour according to the chemotherapy context: adjuvant or metastatic setting.

Detailed Study Description

This is a longitudinal, observational, prospective, multicentre, cohort study, conducted in France among a representative sample of public and/or private hospital-based oncologists. Data will be collected by the investigator during three visits using data available in the patient medical record and obtained from patient questioning and clinical examination performed during the consultations: - Baseline visit: prescription of Nivestim®. - Follow-up visit: during the first cycle of chemotherapy after the first course of Nivestim®. - Final visit: after the last cycle of chemotherapy or 16-18 weeks after inclusion.

Clinical Study Identifier: NCT02454530

Contact Investigators or Research Sites near you

Start Over

Pfizer CT.gov Call Center

CH William Morey Service d'Oncologie M dicale
Chalon Sur Saone Cedex, France
  Connect »